News | November 15, 2023
IOL Chemicals and Pharmaceuticals Q2 PAT jumps 141% to Rs. 37.8 Cr
EBITDA for Q2 FY24 at Rs. 71.2 crore as compared to Rs. 79.9 crore QoQ
EBITDA for Q2 FY24 at Rs. 71.2 crore as compared to Rs. 79.9 crore QoQ
Phase 3 data expected in the second half of 2024
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
Yesafili, received marketing authorization approval from the European Commission for the European Union
Expanded collaboration with Vanguard Renewables aims to significantly increase the productivity of US renewable natural gas generation
This collaboration underscores WOTR's unwavering commitment to strengthening rural communities against the unpredictable variations of climate change
Sales in the US region grew well, partially offset by the decline in the LATAM and European regions
he company posted total income during Q2 FY24 at Rs. 12.86 crore
European operations' revenue grew 58.4% to Rs 599.7 crore
US business grew by +12.8% YoY
Subscribe To Our Newsletter & Stay Updated
